Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Cholangiocarcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Biliary Tract Cancer (389
)
Gallbladder Cancer (45
)
Biliary Tract Cancer (389
)
Gallbladder Cancer (45
)
›
Associations
(219)
News
Trials
Search handles
@Amitmahipal79
@ArndtVogel
@BenWestphalen
@CathyEngMD
@CtiaGaspar8
@DrBonillaOnc
@DrChoueiri
@DrR_DUNNE
@DrShubhamPant
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@DucreuxMichel
@FAndreMD
@FlavioRochaMD
@FunchainMD
@GABOUALFA
@GIcancerDoc
@GlopesMd
@HKennecke
@IbrahimSahinMD1
@JDekervel
@Ja_Capdevila
@JavleMilind
@JiaJennyLiu
@KSainiMD
@LesinskiLab
@LorenzaRimassa
@MPishvaian
@MadisonConces
@MarkYarchoan
@MiteshBorad
@NicoleKuderer
@OncoThor
@OsamaRahma2
@PestanaRC
@RenoHemonc
@SKamath_MD
@SamLubner
@ShaalanBeg
@SirohiBhawna
@StephenVLiu
@SyedAAhmad5
@TiansterZhang
@VivekSubbiah
@bruixj
@cancerassassin1
@davidhenrymd
@drjasonstarr
@drkpavithran
@drlauragoff
@drymtn
@fedenichetti
@ilyassahinMD
@jasonlukemd
@jonathanloree
@jsoriamd
@kmody29
@marklewismd
@mtmdphd
@neerajaiims
@pashtoonkasi
@rachnatshroff
@scottrberry
@shilpaonc
@singhv2003
@weldeiry
Search handles
@Amitmahipal79
@ArndtVogel
@BenWestphalen
@CathyEngMD
@CtiaGaspar8
@DrBonillaOnc
@DrChoueiri
@DrR_DUNNE
@DrShubhamPant
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@DucreuxMichel
@FAndreMD
@FlavioRochaMD
@FunchainMD
@GABOUALFA
@GIcancerDoc
@GlopesMd
@HKennecke
@IbrahimSahinMD1
@JDekervel
@Ja_Capdevila
@JavleMilind
@JiaJennyLiu
@KSainiMD
@LesinskiLab
@LorenzaRimassa
@MPishvaian
@MadisonConces
@MarkYarchoan
@MiteshBorad
@NicoleKuderer
@OncoThor
@OsamaRahma2
@PestanaRC
@RenoHemonc
@SKamath_MD
@SamLubner
@ShaalanBeg
@SirohiBhawna
@StephenVLiu
@SyedAAhmad5
@TiansterZhang
@VivekSubbiah
@bruixj
@cancerassassin1
@davidhenrymd
@drjasonstarr
@drkpavithran
@drlauragoff
@drymtn
@fedenichetti
@ilyassahinMD
@jasonlukemd
@jonathanloree
@jsoriamd
@kmody29
@marklewismd
@mtmdphd
@neerajaiims
@pashtoonkasi
@rachnatshroff
@scottrberry
@shilpaonc
@singhv2003
@weldeiry
Filter by
Latest
9ms
We had summarized some of the HER2 data in colorectal cancer. The space in cholangiocarcinoma is quickly expanding with bispecifics and other drugs as mentioned. Choose/pivot to #clinicaltrials. If not available, choose something that has ✅blood brain barrier 🧠 penetration. https://t.co/9HKqjJ8EkS (@pashtoonkasi)
9 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
10ms
#Italian real-world evidence of #durvalumab, gemcitabine, cisplatin in advanced #biliarytractcancer #cholangiocarcinoma #CCA #BTC @LiverInt @casadei_gardini @lonardi_sara @Mom_enji @HUNIMED @HumanitasMilano https://t.co/ENsCg2QXMK (@LorenzaRimassa)
10 months ago
Clinical • HEOR • Real-world evidence • Real-world • Metastases
|
cisplatin • Imfinzi (durvalumab) • gemcitabine
10ms
In their exciting talk, Dr. @GIcancerDoc and Dr Azad overviewing updates on colorectal cancer and cholangiocarcinoma and precision medicine approaches for these two important diseases‼️ @AnwaarSaeed3 @teekayowo @UPMCHillmanCC #PittsburghOncologySymposium ❗️ (@IbrahimSahinMD1)
10 months ago
10ms
I am pleased to have planned the Rad Onc speakers- very excited to welcome @eugenekoay and @KrishanJethwa for talks on cholangiocarcinoma and mCRC respectively! Please join us! (@nbn426)
10 months ago
10ms
Our last paper : targeted therapy with ivosidenib for IDH1 mutated intrahepatic cholangiocarcinoma! A further step forward to tailored treatment! @LorenzaRimassa https://t.co/n0z0sVjgRy (@casadei_gardini)
10 months ago
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Tibsovo (ivosidenib)
10ms
The Cholangiocarcinoma Conference - Molecular Drivers, Microenvironment and Precision Medicine takes place in California from August 13-17th. @staclinds and @LewisRobertsMD are presenting about Genome-wide Association Studies in CCA. Register today at https://t.co/dGzMMtSz3Z. (@curecc)
10 months ago
10ms
Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2023 Las Vegas, NV US November 10, 2023 to November 11, 2023 Via @MayoMedEd (Thanks for the heads-up @MiteshBorad!) #hpbcsm #cholangiocarcinoma #biliarytractcancer #bileductcancer #gioncology https://t.co/iP2LnFZUQz (@ccadigest)
10 months ago
10ms
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma @JNCI_Now https://t.co/xHUSnv96Qs 👉 Low rates of molecular profiling & 🎯💊in ECC 👉Druggable GA in up 40% of cases 😅use tissue, blood or bile for NGS @myESMO… https://t.co/HdpfHHRn40 (@ArndtVogel)
10 months ago
Clinical • Next-generation sequencing
10ms
🎥@ArndtVogel discusses the latest developments in FGFR inhibition in hepatobiliary cancer. Pemigatinib and futibatinib show promise in cholangiocarcinoma, and RLY-4008 offers reduced toxicity: ➡️https://t.co/Fk9WqYbQcp⬅️ #WCGIC23 @myESMO #HPBCsm (@VJOncology)
10 months ago
Lytgobi (futibatinib) • Pemazyre (pemigatinib) • lirafugratinib (RLY-4008)
10ms
European Commission Grants Conditional Marketing Authorization for Futibatinib for the Treatment of Adults With Cholangiocarcinoma - @ArndtVogel #cancer #cancercare #drugs #futibatinib #cholangiocarcinoma #oncology #oncodaily https://t.co/m4FxYyxVv3 (@oncodaily)
10 months ago
European regulatory
|
Lytgobi (futibatinib)
10ms
Oof. I worry about need to instrument the biliary tree if RnY. Would seriously consider B1 recon in this case. A lot would just depend on intraop feel. Where the tension is, how the duct looks. Etc. Transcystic cholangiogram can be really helpful. (@LeahTatebe)
10 months ago
10ms
European Commission Grants Conditional Marketing Authorization for Futibatinib for the Treatment of Adults With #Cholangiocarcinoma 😅Finally, good news for our patients in Europe as well 👉Efficacy demonstrated in FOENIX-CCA2 @myESMO @EASLnews @ILCAnews @OncoAlert #livertwitter (@ArndtVogel)
10 months ago
Clinical • European regulatory
|
Lytgobi (futibatinib)
10ms
Using the US national mortality database 2017-2021,Intrahepatic cholangiocarcinoma -related mortality continued to increase, HCC-related mortality tended to decline mainly due to a decline in mortality due to viral hepatitis https://t.co/yua2ngr1Bl @LiverInt @GCholankeril (@bcm_gihep)
10 months ago
10ms
Tremendous thanks to @curecc for their generous support, and the mentorship of @eugenekoay @JavleMilind & the team @MDAndersonNews; it’s a privilege to help care for #cholangiocarcinoma patients, who are among the most inspiring folks you will ever meet. #cureCCA #CCAhope (@ebludmir)
10 months ago
Clinical
10ms
🚨 NEO-GAP is 📝 @AnnSurgOncol 🚨 ☝🏽prospective trial of #neoadjuvant chemotherapy for intrahepatic #cholangiocarcinoma. True multiD effort from @curecc #ICRN laying foundation for future studies 🙏🏼 @OncoAlert @ASCO @SocSurgOnc @IHPBA @SSATNews @CcaEns https://t.co/zRWRF7ID0M (@FlavioRochaMD)
10 months ago
Clinical
10ms
Dr. Ju Dong Yang @JuDongYang1 is a co-author on the @NatRevClinOncol paper “#Cholangiocarcinoma — Novel Biological Insights and Therapeutic Strategies” highlighting clinical management & oncogenic drivers of the disease. @CedarsSinaiMed https://t.co/TYHICGMikt (@CSCancerCenter)
10 months ago
Clinical
10ms
Great review on the current state of immunotherapy in BTC authored by our senior fellow & soon-to-be junior faculty, Justin Lo: https://t.co/nW18tYn4fU #cholangiocarcinoma #immunotherapy @VUMCDiscoveries @VUMCHemOnc @CathyEngMD @drlauragoff @RajivAgarwalMD @jordanberlin5 @curecc (@HeumannThatcher)
10 months ago
Review
10ms
If you are strong believer in accionable targets in bile duct cancer, then here you are! @GIcancerDoc #WCGIC2023 Great summary! 👏 (@Juanmaoconnor)
10 months ago
10ms
Potentially revolutionary treatment targets in #Fibroblasts #HCC #HepatocellularCarcinoma #Cholangiocarcinoma #LiverTwitter #OncTwitter @OncoAlert @LancetGastroHep @Rob__Brierley @RashidLui @StephenLChan1 (@wonglaihung)
10 months ago
10ms
🔥How could you best kick-off #WCGIC2023? 👉Looking forward to an exciting @PeerVoice Educational Event with my fantastic colleagues @DrAngelaLamarca & @NicolaNormanno 👉Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise @myESMO @ilca @EASLedu… https://t.co/Y1hfJYopFG (@ArndtVogel)
10 months ago
Educational event
10ms
🔥How could you best kick-off #WCGIC2023? 👉Looking forward to an exciting @PeerVoice Educational Event with my fantastic colleagues @DrAngelaLamarca & @NicolaNormanno 👉Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise @myESMO @ilca @EASLedu… https://t.co/O8uqP6tQHR (@ArndtVogel)
10 months ago
Educational event
10ms
Glad to discuss the options for #FGFR inhibition in the management of #cholangiocarcinoma #CCA #biliarytractcancer with @DrAngelaLamarca and @ArndtVogel @HUNIMED @HumanitasMilano @PeerVoice (@LorenzaRimassa)
10 months ago
10ms
Cholangiocarcinoma Foundation webinar: How liquid biopsies are helping with precision medicine for patients with cancer, featuring @pashtoonkasi Via @curecc https://t.co/b6RsdTQtFo (@ccadigest)
10 months ago
Clinical • Liquid biopsy • Biopsy
10ms
#thinktank on systemic treatment pf #HCC and #cholangiocarcinoma has started @DrAngelaLamarca showed data on combination of systemic tx with lororegional txs. #EASLCongress (@massimoiava)
10 months ago
10ms
@ArndtVogel concludes the #EASLCongress PG course with discussion about cholangiocarcinoma. Increasing treatment options. Molecular testing recommended for treatment selection #LiverTwitter @EASLedu (@sconglymd)
10 months ago
10ms
Postgraduate Course: From NAFLD to liver cancer - Management of HCC & cholangiocarcinoma in patients with NAFLD #EASLCongress 👉On to the final session focusing on surgery, transplantation & systemic 💊for HCC & BTC with J. Llovet, P. Burra @NaultJc @ArndtVogel 👏Kudos to the… https://t.co/Lc3ilwD2s0 (@ArndtVogel)
10 months ago
Clinical • Surgery
10ms
Postgraduate Course: From NAFLD to liver cancer - Management of HCC & cholangiocarcinoma in pts with NAFLD #EASLCongress 👉On to the final session focusing on surgery, transplantation & systemic 💊for HCC & BTC with J. Llovet, P. Burra @NaultJc @ArndtVogel 👏Kudos to the… https://t.co/S0rUTbq816 (@ArndtVogel)
10 months ago
Clinical • Surgery
10ms
Looking forward to this webinar by @curecc& @pashtoonkasi 6/22 1pm PST “How liquid biopsies are helping w/ #precisionmedicine for pts w/cancer & how it may help increase opportunities for precision med based therapies for pts” #cholangiocarcinoma🩸🧬💚 https://t.co/hlgsCOZUT3 (@pfox2100)
10 months ago
Clinical • Liquid biopsy • Biopsy
10ms
Nice summary on recent developments in cholangiocarcinoma therapy from the experts @SumeraIlyasMD and colleagues (@DrAngelaLamarca @sapisochin @SilviaAffo, Lipika Goyal, Ju Dong Yang and Greg Gores) @curecc #livercancer https://t.co/0gGC1ddVMK (@TimGreten)
10 months ago
10ms
#EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR fusion-positive advanced #cholangiocarcinoma https://t.co/jBV3Ozice5 #fondazionebonadonna #cancerresearch #oncology @CarmenCriscit @BianchiniGP @mauricallari (@FondazioneBona1)
10 months ago
Metastases
|
FGFR fusion
10ms
🔥Options & Opportunities in #Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations 🧐What Are the Options? Interested? 👉PeerVoice activity by @DrAngelaLamarca @LorenzaRimassa & @ArndtVogel 👇 https://t.co/Xs4OAtDA3f @myESMO @OncoAlert @Easledu @ilca @curecc… https://t.co/nYfuD6ITRH (@ArndtVogel)
10 months ago
FGFR (Fibroblast Growth Factor Receptor)
10ms
Novel Approaches for Targeting #FGFR Alterations in #CCA #cholangiocarcinoma @DrAngelaLamarca @ArndtVogel @HUNIMED @HumanitasMilano @ILCAnews @CharityAMMF @CcaEns @curecc @CholangioNet @CCA_Alliance (@LorenzaRimassa)
10 months ago
FGFR (Fibroblast Growth Factor Receptor)
11ms
Prognostic impact of proximal ductal margin status in perihilar cholangiocarcinoma according to the presence or absence of lymph node metastasis @SurgJournal @FlavioRochaMD @shimulshah73 https://t.co/vUI3MttQhJ (@SyedAAhmad5)
11 months ago
11ms
Honored by the invitation to co-host this Session with @LewisRobertsMD at the Cholangiocarcinoma Conference - FASEB in California in August, see you there! @MayoCancerCare @NCIResearchCtr @theNCI @NCICCR_MOS @FASEBorg (@CeciliaMonge4)
11 months ago
11ms
Hepatocholangiocarcinoma 2.2 cm - 50% of each component. High Grade. Underwent a surgery with free margin. pT1a. Would you recommend any adjuvant treatment. @ArndtVogel @GABOUALFA Thanks (@pam65230529)
11 months ago
Clinical • Surgery
11ms
11/21 #TumorBoardTuesday ✅In #cholangiocarcinoma @DrShubhamPant & Dr. Nakamura🗣️exciting data on HER2🎯💊 👉Tx w/ tucat+trastuz➡️a 47% ORR in 30 Pts & 👉Zanidatamab➡️a 41% ORR in 80 Pts ✅Giving us two new options for these patients that we might be able to use in sequence❓ (@MPishvaian)
11 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
zanidatamab (ZW25)
11ms
This field is updated so fast, recently. Thank you @ArndtVogel #cholangiocarcinoma (@changhoon_yoo)
11 months ago
11ms
🔥Recent advances in systemic therapy for advanced intrahepatic cholangiocarcinoma 👏Comprehensive & detailed update on 💊options for CCC > IO & 🎯therapies by @changhoon_yoo & colleagues 👇https://t.co/yC1W2Kie8e in Liver Cancer @myESMO @EASLedu @OncoAlert @ILCAnews (@ArndtVogel)
11 months ago
Metastases
11ms
For the most part, HER-2 status and T-DxD does not appear to make much of a difference in #PancreaticCancer. But quite effective in appropriately selected bile duct cancers. #ASCO23 So much of “pancreato-biliary” is really pancreatic versus biliary. (@Aiims1742)
11 months ago
HER-2 (Human epidermal growth factor receptor 2)
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
11ms
💥Highly recommended article: The role of tumor microenvironment in cholangiocarcinoma #CCA #TME #HCC #meded #livertwitter 📕Read: https://t.co/XLaanGdbmz ⬇Video abstrac⬇ https://t.co/C8aTSvSAfx @CharityAMMF @GABOUALFA @timpawlik @LorenzaRimassa @ILCAnews @AASLDtweets (@HepatomaRes)
11 months ago
Video
11ms
Dr Lamarca, my wife's treatment for cholangiocarcinoma has not been successful. Can you offer some guidance please? Dovermike52@gmail.com Thank you (@DoverMike54)
11 months ago
11ms
#ASCO2023 #Cholangiocarcinoma #LiverTwitter #hepatocellularcarcinoma @curecc @VUMC_Cancer @VUMCHemOnc @CathyEngMD @drlauragoff @RajivAgarwalMD @KristenCiombor @CardinMD @jordanberlin5 @MarkYarchoan Takeaways from the Liver, Biliary, Panc Oral Sessions from ASCO 2023 (see below) (@HeumannThatcher)
11 months ago
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login